GSK PLC has seen its RSV vaccines shoot to blockbuster status in little over six months, according to the Financial Times citing analysts.
The term blockbuster refers to any drug with annual sales of more than US$1 billion, a landmark likely to have been passed by Arexvy inoculation in the final quarter of last year.
GKS’s jab competes with a Pfizer Inc (NYSE:PFE) look-alike, though doctors appear to be prescribing Arexvy in far greater quantities than rival Abrysvo.
Estimated to be worth just under US$2 billion in 2022, the RSV market is expected to peak in 2031 at US$8.1 billion, according to research.
While it presents as nothing more than a mild cold for most people affected, RSV, or respiratory syncytial virus, can have a life-threatening impact on the elderly and very young.
GSK will provide an update on Wednesday on the health of its drugs portfolio, including another fast grower, the shingles drug Shingrix, along with its full-year results.